News | October 25, 2021
Biocon Q2FY22 in line with estimates, better margins: ICICI Direct
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
The company will use the capital for building its team, product development, marketing, and setting up in-school clinics to deliver connected health to one million families
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Domestic business was up 41.9% YoY and 27.7% QoQ
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
It plays a pivotal role in monitoring pharmaceutical pricing
The data should be submitted by August 12th 2021
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
Subscribe To Our Newsletter & Stay Updated
